EE04391B1 - Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid - Google Patents
Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodidInfo
- Publication number
- EE04391B1 EE04391B1 EEP200000589A EEP200000589A EE04391B1 EE 04391 B1 EE04391 B1 EE 04391B1 EE P200000589 A EEP200000589 A EE P200000589A EE P200000589 A EEP200000589 A EE P200000589A EE 04391 B1 EE04391 B1 EE 04391B1
- Authority
- EE
- Estonia
- Prior art keywords
- superlaggregates
- tablets
- formulations
- making
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8092598P | 1998-04-07 | 1998-04-07 | |
PCT/US1999/007228 WO1999051239A1 (en) | 1998-04-07 | 1999-04-01 | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200000589A EE200000589A (et) | 2002-04-15 |
EE04391B1 true EE04391B1 (et) | 2004-12-15 |
Family
ID=22160544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200000589A EE04391B1 (et) | 1998-04-07 | 1999-04-01 | Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid |
Country Status (27)
Country | Link |
---|---|
US (2) | US6238695B1 (xx) |
EP (1) | EP1067936B1 (xx) |
JP (1) | JP2002510634A (xx) |
KR (1) | KR100634253B1 (xx) |
CN (1) | CN1146419C (xx) |
AR (1) | AR019031A1 (xx) |
AT (1) | ATE223719T1 (xx) |
AU (1) | AU756422B2 (xx) |
BR (1) | BR9908810A (xx) |
CA (1) | CA2321523C (xx) |
CZ (1) | CZ300850B6 (xx) |
DE (1) | DE69902893T2 (xx) |
DK (1) | DK1067936T3 (xx) |
EA (1) | EA003217B1 (xx) |
EE (1) | EE04391B1 (xx) |
ES (1) | ES2181417T3 (xx) |
HU (1) | HU228498B1 (xx) |
IL (1) | IL138078A (xx) |
NO (1) | NO325824B1 (xx) |
NZ (1) | NZ507566A (xx) |
PL (1) | PL194309B1 (xx) |
PT (1) | PT1067936E (xx) |
SK (1) | SK284655B6 (xx) |
TW (1) | TW576741B (xx) |
UA (1) | UA72207C2 (xx) |
WO (1) | WO1999051239A1 (xx) |
ZA (1) | ZA200004313B (xx) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA72207C2 (uk) * | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
EP1332757B1 (en) * | 1998-05-27 | 2012-06-13 | Merck Sharp & Dohme Corp. | Efavirenz compressed tablet formulation |
US20010014352A1 (en) | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
KR20070040426A (ko) * | 1998-06-11 | 2007-04-16 | 파마시아 앤드 업존 캄파니 엘엘씨 | 빠르게 침전하는 약물의 정제 제제 |
US20050053678A1 (en) * | 2001-10-03 | 2005-03-10 | Gow Robert T. | Methods and compositions for betel nut chewing gum |
US20050069596A1 (en) * | 2001-10-03 | 2005-03-31 | Gow Robert T. | Compositions and methods comprising kava and anti-anxiety compounds |
US7291352B2 (en) | 2001-10-03 | 2007-11-06 | Herbalscience Llc | Methods and compositions for oral delivery of Areca and mate' or theobromine |
US7037524B2 (en) * | 2001-10-03 | 2006-05-02 | Herbalscience, Llc | Oral delivery of a botanical |
EP1448170A4 (en) * | 2001-11-27 | 2010-05-12 | Bristol Myers Squibb Co | EFAVIRENZ STAMP PREPARATIONS HAVING UNIQUE BIOPHARMACEUTICAL CHARACTERISTICS |
FR2834212B1 (fr) * | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
US20050037025A1 (en) * | 2002-10-03 | 2005-02-17 | Gow Robert T. | Methods and compositions comprising kava and mate' or theobromine |
US20040224916A1 (en) | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
US8021682B2 (en) * | 2004-08-13 | 2011-09-20 | Gallipot, Inc. | Palatable suspending vehicle for pharmaceutical ingredients |
US20060099253A1 (en) * | 2004-10-20 | 2006-05-11 | Wyeth | Antibiotic product formulation |
TWI375560B (en) * | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
EP1912730A2 (en) * | 2005-07-28 | 2008-04-23 | Isp Investments Inc. | Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced |
WO2007013047A2 (en) * | 2005-07-29 | 2007-02-01 | Ranbaxy Laboratories Limited | Water-dispersible anti-retroviral pharmaceutical compositions |
AU2006325404B2 (en) * | 2005-12-14 | 2012-03-01 | Cipla Limited | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit |
EP2043613A1 (en) * | 2006-07-14 | 2009-04-08 | Fmc Corporation | Solid form |
MX2009002873A (es) * | 2006-09-14 | 2009-05-19 | Chemlink Lab Llc | Metodo para preparar formas de dosis solida que forman una pasta, crema o gel cuando se diluyen para uso final. |
US20080152717A1 (en) * | 2006-12-14 | 2008-06-26 | Isp Investments, Inc. | Amorphous valsartan and the production thereof |
US8613946B2 (en) * | 2006-12-21 | 2013-12-24 | Isp Investment Inc. | Carotenoids of enhanced bioavailability |
US10189957B2 (en) * | 2007-01-26 | 2019-01-29 | Isp Investments Llc | Formulation process method to produce spray dried products |
US20080181961A1 (en) * | 2007-01-26 | 2008-07-31 | Isp Investments, Inc. | Amorphous oxcarbazepine and the production thereof |
US20080311162A1 (en) * | 2007-05-16 | 2008-12-18 | Olivia Darmuzey | Solid form |
JP2010536798A (ja) * | 2007-08-17 | 2010-12-02 | テバ ファーマシューティカル インダストリーズ リミティド | 難溶性薬物の生体利用率を制御するための方法及び組成物 |
WO2010008719A2 (en) * | 2008-06-16 | 2010-01-21 | Schering Corporation | Oral pharmaceutical formulations of vla-4 antagonists |
WO2010125572A1 (en) * | 2009-04-29 | 2010-11-04 | Hetero Research Foundation | Compressed tablets and capsules containing efavirenz |
NZ627826A (en) | 2010-01-27 | 2016-01-29 | Viiv Healthcare Co | Antiviral combinations involving (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide |
NZ602955A (en) * | 2010-04-20 | 2015-02-27 | Cipla Ltd | Pharmaceutical composition comprising efavirenz |
US20130115237A1 (en) | 2010-06-09 | 2013-05-09 | Vaccine Technologies, Incorporated | Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment |
CN102872019A (zh) * | 2012-09-17 | 2013-01-16 | 北京阜康仁生物制药科技有限公司 | 一种采用微粉化技术的依非韦伦制剂 |
IN2013MU03370A (xx) | 2013-10-25 | 2015-09-25 | Cipla Ltd | |
PE20180690A1 (es) | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
WO2017029226A1 (en) | 2015-08-14 | 2017-02-23 | Sandoz Ag | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz |
CN114404377B (zh) * | 2022-01-10 | 2023-07-25 | 安徽贝克生物制药有限公司 | 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7084587A (en) | 1986-04-01 | 1987-10-20 | Upjohn Company, The | Methylprednisolone/sodium carboxymethyl starch tablet composition |
CA2002137A1 (en) * | 1989-04-28 | 1990-10-28 | Genkichi Ohta | Anti-human immunodeficiency virus composition |
DK0577913T3 (da) * | 1992-07-08 | 1998-01-26 | Santen Oy | Ophthalmisk præparat indeholdende timolol-hemihydrat |
US5519021A (en) | 1992-08-07 | 1996-05-21 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
AU1694295A (en) * | 1994-01-28 | 1995-08-15 | Merck & Co., Inc. | Benzoxazinones as inhibitors of hiv reverse transcriptase |
US5663467A (en) * | 1995-01-23 | 1997-09-02 | Merck & Co., Inc. | Synthesis of cyclopropylacetylene |
IT1281502B1 (it) * | 1995-06-13 | 1998-02-18 | Sardinian Antiviral Research C | Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della |
UA72207C2 (uk) * | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
PE20000559A1 (es) | 1998-05-27 | 2000-07-05 | Merck & Co Inc | Formulacion de tabletas comprimidas de efavirenz |
-
1999
- 1999-01-04 UA UA2000105657A patent/UA72207C2/uk unknown
- 1999-04-01 EE EEP200000589A patent/EE04391B1/xx unknown
- 1999-04-01 ES ES99916286T patent/ES2181417T3/es not_active Expired - Lifetime
- 1999-04-01 HU HU0101517A patent/HU228498B1/hu unknown
- 1999-04-01 IL IL13807899A patent/IL138078A/xx not_active IP Right Cessation
- 1999-04-01 SK SK1461-2000A patent/SK284655B6/sk not_active IP Right Cessation
- 1999-04-01 DE DE69902893T patent/DE69902893T2/de not_active Expired - Lifetime
- 1999-04-01 AU AU34637/99A patent/AU756422B2/en not_active Expired
- 1999-04-01 PL PL99343421A patent/PL194309B1/pl unknown
- 1999-04-01 KR KR1020007011091A patent/KR100634253B1/ko not_active IP Right Cessation
- 1999-04-01 DK DK99916286T patent/DK1067936T3/da active
- 1999-04-01 NZ NZ507566A patent/NZ507566A/xx not_active IP Right Cessation
- 1999-04-01 PT PT99916286T patent/PT1067936E/pt unknown
- 1999-04-01 CA CA002321523A patent/CA2321523C/en not_active Expired - Lifetime
- 1999-04-01 JP JP2000542010A patent/JP2002510634A/ja active Pending
- 1999-04-01 EP EP99916286A patent/EP1067936B1/en not_active Expired - Lifetime
- 1999-04-01 AT AT99916286T patent/ATE223719T1/de active
- 1999-04-01 CN CNB998048011A patent/CN1146419C/zh not_active Ceased
- 1999-04-01 EA EA200001030A patent/EA003217B1/ru not_active IP Right Cessation
- 1999-04-01 BR BR9908810-0A patent/BR9908810A/pt not_active Application Discontinuation
- 1999-04-01 WO PCT/US1999/007228 patent/WO1999051239A1/en active IP Right Grant
- 1999-04-01 CZ CZ20003571A patent/CZ300850B6/cs not_active IP Right Cessation
- 1999-04-06 US US09/286,902 patent/US6238695B1/en not_active Expired - Lifetime
- 1999-04-07 AR ARP990101586A patent/AR019031A1/es not_active Application Discontinuation
- 1999-06-09 TW TW088105520A patent/TW576741B/zh not_active IP Right Cessation
-
2000
- 2000-08-22 ZA ZA200004313A patent/ZA200004313B/xx unknown
- 2000-10-06 NO NO20005043A patent/NO325824B1/no not_active IP Right Cessation
-
2001
- 2001-04-02 US US09/824,071 patent/US6555133B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE04391B1 (et) | Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid | |
NO996433D0 (no) | Nye formuleringer av legemidler, fremgangsmåter for fremstilling derav og fremgangsmåter for anvendelse derav | |
NO20001409L (no) | Karboksamidotiazolderivater, fremgangsmÕte for fremstilling derav og farmasøytiske blandinger | |
HUP0103913A3 (en) | Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same | |
NO971485D0 (no) | Antineoplastiske kakaoekstrakter, metoder for fremstilling og anvendelse | |
NO20004643D0 (no) | Polymerbaserte raskt oppløselige tabletter og fremgangsmÕte for fremstilling derav | |
DK1112266T3 (da) | Substituerede 4-amino-2-arylpyrimidiner, fremstilling og anvendelse deraf og farmaceutiske præparater indeholdende dem | |
IS5662A (is) | Þíenýlasólýlalkoxýetanamín, framleiðsla þeirra ognotkun sem lyf | |
NO20032332D0 (no) | Benzodiazepinderivatforbindelser, fremgangsmåte til fremstilling og anvendelse derav | |
IS2821B (is) | Amínóalkýlbensóýl-bensófúran eða bensóþíófenafleiður, aðferð til framleiðslu þeirra og samsetningar sem innihalda þær | |
NO20012963L (no) | Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler | |
NO20015659L (no) | Purinderivater, fremstillingsmetode og farmasöytiske preparater inneholdende disse | |
HK1044156A1 (en) | Camptothecin analogs and methods of preparation thereof. | |
DK1131052T3 (da) | Vaginalt indgivelige progesteron-holdige tabletter og fremgangsmåde til fremstilling deraf | |
PL350902A1 (en) | Pyridothiene diazepins, method of obtaining them and pharmacological compositions containing them | |
PL342453A1 (en) | Biphenylsulphonylcyanamides, method of obtaining them and their application as drugs | |
ZA99168B (en) | Pharmaceutical formulations and processes for their preparation. | |
HUP0102116A3 (en) | Paroxetine ascorbate, process for its preparation and its pharmaceutical use | |
DK1076651T3 (da) | Substituerede sulfonylcyanamider, fremgangsmåde til fremstilling heraf og anvendelsen heraf som lægemidler | |
SI1067936T1 (en) | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants | |
DK1259523T3 (da) | Pluraflaviner og derivater deraf, fremgangsmåde til fremstilling og anvendelse deraf | |
PL332894A1 (en) | Hadgehog protein conjugate, method of obtaining same, pharmaceutic composition and method of obtaining same, hedgehog protein | |
EE200100474A (et) | Antratsükliinide L-arabinodisahhariidid, nende valmistamise meetodid ning neid sisaldavad ravimkoostised | |
DK1047668T3 (da) | Triazepinoner, fremgangsmåde til fremstilling deraf og terapeutisk anvendelse deraf | |
DZ3065A1 (fr) | Formulations pour la toux à base de plantes médicinales et procédés pour leur préparation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB4A | Valid patent at the end of a year |
Effective date: 20041231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20051231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20071231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |